Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01940796 · ClinicalTrials.gov registry record · Phase 1
Phase I Trial of Brentuximab Vedotin for Refractory Chronic Graft-vs.-Host Disease (GVHD)
A Phase 1 study, sponsored by Massachusetts General Hospital.
- Terminated
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
NCT01940796: Clinical Trial Phase 1 study, sponsored by Massachusetts General Hospital.
NCT01940796 is a Phase 1 study that was terminated before completion, run by Massachusetts General Hospital. The registered enrollment target is 19 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01940796, a Phase 1 study, was terminated before completion, sponsored by Massachusetts General Hospital.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
Study Summary
This research study is trying to determine the safest dose of Brentuximab Vedotin that can be given to patients with chronic GVHD and see if chronic GVHD improves.
Interventions
- DRUG Brentuximab Vedotin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2013-10 |
| Est. Completion | 2016-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01940796
The ClinicalTrials.gov registry entry for NCT01940796 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Brentuximab Vedotin is the first listed.
NCT01940796 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01940796 about?
NCT01940796 is a clinical study titled "Phase I Trial of Brentuximab Vedotin for Refractory Chronic Graft-vs.-Host Disease (GVHD)". This research study is trying to determine the safest dose of Brentuximab Vedotin that can be given to patients with chronic GVHD and see if chronic GVHD improves.
What is the current status of trial NCT01940796?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2013-10. Estimated completion is 2016-12.
What interventions are being tested in trial NCT01940796?
The interventions under investigation include: Brentuximab Vedotin (DRUG).
Who is sponsoring clinical trial NCT01940796?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.